Windtree Therapeutics
WINT
Market cap $1.15M

0.7150 USD

+0.0130

1.85%

At close Oct 11, 4:00 PM EDT

After hours

0.7200

+0.0050

0.70%

1 day

1.85%

5 days

-34.40%

1 month

-76.56%

3 months

-81.43%

6 months

-89.52%

Year to date

-94.31%

1 year

-96.52%

5 years

-99.99%

About: Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Employees: 20

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

7.68% less ownership

Funds ownership: 7.94% [Q1] → 0.26% (-7.68%) [Q2]

44% less funds holding

Funds holding: 9 [Q1] → 5 (-4) [Q2]

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

98% less capital invested

Capital invested by funds: $239K [Q1] → $4.87K (-$234K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for WINT.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about WINT published over the past 30 days

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Istaroxime treatment significantly improved systolic blood pressure as well as cardiac output and renal function without increasing heart rate or clinically significant arrythmias

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

New Istaroxime Phase 2b clinical results to be presented by Windtree and top cardiology expert Review of cardiogenic shock and other programs, including Windtree's strategy and planned near-term milestones WARRINGTON, Pa., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it will hold a virtual Investor Day Presentation on October 1 at 3pm ET.

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the second quarter ended June 30, 2024 and provided key business updates.

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Windtree Announces New Additions and Changes to Its Board of Directors

WARRINGTON, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced changes to its board of directors, effective August 13, 2024, which include the appointment of Saundra Pelletier and Jed Latkin as two new independent directors with significant public company director and executive leadership.

Windtree Announces New Additions and Changes to Its Board of Directors

Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?

Windtree Therapeutics (NASDAQ: WINT ) stock is rocketing higher on Friday after the biotechnology company provided an update on its clinical trial of istaroxime. Windtree Therapeutics notes that it is expecting its Phase 2 Phase 2 SEISMiC Extension Study to complete enrollment within the company weeks.

Why Is Windtree Therapeutics (WINT) Stock Up 116% Today?

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data Nearing completion of enrollment, the SEISMiC Extension Phase 2b study in early cardiogenic shock patients is set to deliver new data

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

Windtree Therapeutics Regains Compliance with Nasdaq

WARRINGTON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") informing Windtree that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.

Windtree Therapeutics Regains Compliance with Nasdaq

What made Windtree Therapeutics stock tank 20% on Monday?

Windtree Therapeutics Inc (NASDAQ: WINT) is down nearly 20% on Monday even though there hasn't been any specific news that may have caused that decline. Here's what may be weighing on Windtree Therapeutics stock Investors may be continuing to respond to a few updates that $WINT has posted in recent days.

What made Windtree Therapeutics stock tank 20% on Monday?

Windtree Therapeutics Announces Reverse Stock Split

WARRINGTON, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NASDAQ: WINT) (“Windtree” or the “Company”), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today announced that the Company's Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 11:59 p.m. Eastern Time on April 19, 2024 and the Company's common stock will open for trading on The Nasdaq Capital Market on a split-adjusted basis under the symbol “WINT” on April 22, 2024. At such time, the Company's common stock will also commence trading under a new CUSIP number, 97382D 501.

Windtree Therapeutics Announces Reverse Stock Split

See News Rankings

Charts implemented using Lightweight Charts™